BioCentury
ARTICLE | Clinical News

REP 2165-Mg: Preliminary Ph II REP 401 data

February 3, 2017 5:35 PM UTC

Preliminary data from 40 treatment-naïve, non-cirrhotic patients with HBeAg-negative chronic HBV infection in the open-label Phase II REP 401 trial showed that once-weekly 250 mg IV REP 2139-Mg and RE...

BCIQ Company Profiles

Replicor Inc.